News|Articles|May 22, 2026
The Shift Pharma Can’t Afford to Miss: From AI Experimentation to Execution
Author(s)EVERSANA
Related Content
Trending on PharmExec
1
Reshoring Pharma and Biotech Manufacturing Ahead of This Summer’s Tariff Deadlines: Q&A with Ryan Last
2
How Regulatory Stringency, Demand Shocks, and Repurposing Reshape Biopharma Strategy in 2026
3
Traditional Healthcare Has a Retention Problem It Refuses to Diagnose
4
Novartis to Acquire Myricx Bio for $1.1 Billion
5